davehulcoop.bsky.social
@davehulcoop.bsky.social
Reposted
The Open Targets Platform autumn release is out! 🍂

We have ingested the full dataset of over 13 million enhancer-gene regulatory interactions in the human genome across 1,458 DNase-seq experiments covering 369 cell types and tissues from the ENCODE-rE2G model

blog.opentargets.org/open-targets...
Open Targets Platform 25.09 has been released!
The September 25 release includes enhancer-gene data predicted by ENCODE-rE2G, molQTL credible sets for targets, new options for the variant structural viewer, and a number of data updates from GWAS C...
blog.opentargets.org
September 18, 2025 at 10:39 AM
Reposted
🧬 New @emblebi.bsky.social service beta launched:
Perturbation Catalogue

🔎 Browse genetic perturbation datasets
🧠 Train models
🧬 Interpret variant function
🧭 Explore gene dependencies

Search, test APIs, suggest datasets, send feedback!
🔗 www.ebi.ac.uk/perturbation...

Funded by @opentargets.org
July 23, 2025 at 10:06 AM
Reposted
Open Targets Platform 25.06 is out now! 🌻

It includes 36% more GWAS credible sets (including from the VA Million Veteran Program study) and a new target interactors view to help nominate potential targets

blog.opentargets.org/open-targets...
Open Targets Platform 25.06 has been released!
This release brings in 36% more GWAS credible sets, association evidence for a target's interactors, revamped data downloads page and molecular structure viewers, gene burden data from the Broad CVDI ...
blog.opentargets.org
June 18, 2025 at 1:49 PM
Very excited to share the latest work of the team @opentargets.org. If you are interested in #targetdiscovery and #genetics check out the latest release of the Open Targets Platform.
Open Targets Platform 25.03 is finally here! 🌼

This update brings in variant, study, and credible set information, uniting the Open Targets Platform and Open Targets Genetics into a one-stop shop for human genetic and target discovery information.

blog.opentargets.org/open-targets...
March 20, 2025 at 9:13 AM
Reposted
What can we learn from 95 projects across 10 years of industry-academic collaboration? 🤝

In a comment for Nature Reviews Drug Discovery, the Open Targets Directors shared their insights on what makes a successful and impactful project 🧪🧬

www.nature.com/articles/d41...
Open Targets: 10 years of partnership in target discovery
The Open Targets consortium was founded in 2014 to translate insights from genetics and functional genomics into identifying and prioritizing therapeutic targets. We highlight key achievements and ins...
www.nature.com
February 18, 2025 at 12:33 PM
Reposted
We're hiring! 👩‍🔬🧬💻

➡ Staff Scientist: high-throughput sc CRIPSR screening in neurodegenerative disease

➡ Data Manager (part time), the point of contact for Open Targets project data

➡ Postdoc: Neurodegenerative Disease Immune Response Modelling

opentargets.org/jobs

#neurojobs #sciencejobs
Jobs - Open Targets
Open Targets is a public-private initiative to generate evidence on the validity of therapeutic targets based on genome-scale experiments and analysis.
opentargets.org
February 4, 2025 at 12:20 PM
Reposted
With the gget opentargets module, you can now interact directly with the Open Targets database from a Python or command line environment

Developed by @lauraluebbert.com, gget is a free, open-source tool enabling efficient querying of large genomic databases 🖥️🧬

blog.opentargets.org/case-study-g...
Case study: gget’s new Open Target module
The new gget opentargets module allows users to communicate directly with the Open Targets database from a Python or command line environment. Amongst other tasks, gget opentargets can quickly find di...
blog.opentargets.org
January 30, 2025 at 11:56 AM
Reposted
🗞️New preprint!

Maria Falaguera developed a method to comprehensively track the accumulation of literature-derived, genetic and clinical evidence linking targets to disease over time, and to identify novel drug target opportunities

🧬🖥️

www.researchsquare.com/article/rs-5...
Temporal trends in novel drug target discovery reveal the increasing importance of human genetic data
Drug approvals involving novel mechanism-of-action targets currently account for about one-fifth of new FDA-approved drugs each year. Developing therapies for novel targets carries added risks, but th...
www.researchsquare.com
January 28, 2025 at 9:51 AM